Literature DB >> 18936378

Usage of blood products in multiple-casualty incidents: the experience of a level I trauma center in Israel.

Dror Soffer1, Josef Klausner, Dan Bar-Zohar, Oded Szold, Carl I Schulman, Pinchas Halpern, Avigail Shimonov, Mara Hareuveni, Ofira Ben-Tal.   

Abstract

OBJECTIVE: To predict how much blood will be needed based on the number of injured patients arriving after a multiple-casualty incident.
DESIGN: A retrospective study evaluating data collected in 18 consecutive terrorist attacks in the city of Tel Aviv between January 1997 and February 2005.
SETTING: A large, urban trauma center. PATIENTS: A total of 986 patients in 18 events. MAIN OUTCOME MEASURES: Number of packed red blood cell (PRBC) units transfused per patient.
RESULTS: A total of 332 U of PRBCs were transfused. Half of the PRBC units were administered as massive transfusions to 4.7% of the patients. The number of PRBC units transfused per patient index (PPI) was related to incident size (mean [SD], 0.70 [1.60] to 1.50 [1.60]). The most frequent major blood group transfused was type O (50%). Half of the units of PRBCs were supplied during the first 2 hours.
CONCLUSIONS: One unit of blood per evacuated victim is sufficient in a small multiple-casualty incident and 2 U is sufficient in a large multiple-casualty incident. Half of the PRBC units should be blood group O.

Entities:  

Mesh:

Year:  2008        PMID: 18936378     DOI: 10.1001/archsurg.143.10.983

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  1 in total

1.  Limitations of Available Blood Products for Massive Transfusion During Mass Casualty Events at US Level 1 Trauma Centers.

Authors:  James Williams; Michael Gustafson; Yu Bai; Samuel Prater; Charles E Wade; Oscar D Guillamondegui; Mansoor Khan; Megan Brenner; Paula Ferrada; Derek Roberts; Tal Horer; David Kauvar; Andrew Kirkpatrick; Carlos Ordonez; Bruno Perreira; Artai Priouzram; Juan Duchesne; Bryan A Cotton
Journal:  Shock       Date:  2021-12-01       Impact factor: 3.454

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.